Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals
One-line summary: RNAi platform biotech (NASDAQ: ARWR); tracked here as an alternative-modality winner if tau proves out in Alzheimer's — its trans-blood-brain-barrier (trans-BBB) shuttle allows IV/subQ dosing, a delivery edge over Biogen's intrathecal ASO.
What it is
Arrowhead develops RNAi (siRNA) therapeutics and is building a trans-BBB delivery shuttle that lets CNS-targeted RNAi be given IV rather than intrathecally — a materially more convenient route than the ASO incumbents.
Why it matters to stock-market
Arrowhead is a candidate beneficiary in biogen-tau-failure-to-brain-shuttle-rerate: if tau proof-of-concept survives the messy diranersen readout, the panel's read is that IV brain-shuttle players capture the value with a plausibly lower efficacy bar given ease of use. Arrowhead's problem-modality (siRNA + trans-BBB shuttle) is positioned against exactly the ASO tolerability limits that muddied Biogen's result.
Key facts
- Trans-BBB shuttle, IV-dosable tau program. john-maraganore in 2026-07-17-podcast-biotech-hangout-episode-189-july-17-2026: "that's why Arrowhead with what they're doing... Arrowhead's program is a Trans BBB shuttle." Contrasted with intrathecal ASOs (Ionis/Biogen) and Alnylam's intrathecal tau program.
- Ease-of-use efficacy edge. paul-matteis earlier (2026-07-10-podcast-biotech-hangout-episode-188-july-10-2026): "The more interesting play are the brain shuttle approaches like Denali and Arrowhead, which can be given IV, and maybe a much lower efficacy bar given ease of use."
Open questions
- No Arrowhead tau efficacy data is cited yet — the thesis is mechanistic (delivery advantage), not clinically proven. See biogen-tau-failure-to-brain-shuttle-rerate.